HS1, a lyn kinase substrate, is abnormally expressed in B-chronic lymphocytic leukemia and correlates with response to fludarabine-based regimen

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Frezzato, Federica ^a,b   Gattazzo, Cristina ^a,b   Martini, Veronica ^a,b   Trimarco, Valentina ^a,b   Teramo, Antonella ^a,b   Carraro, Samuela ^b   Cabrelle, Anna ^a   Ave, Elisa ^a,b   Facco, Monica ^a,b   Zambello, Renato ^a,b   Tibaldi, Elena ^c   Brunati, Anna Maria ^c   Semenzato, Gianpietro ^a,b   Trentin, Livio ^a,b  

^a VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

^b UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; PROTEIN HS1; PROTEIN KINASE LYN; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER SURVIVAL; CELL NUCLEUS; CELL SURVIVAL; CELL TYPE; CELLULAR DISTRIBUTION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SURVIVAL RATE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PROTEINS; CELL NUCLEUS; CYCLOPHOSPHAMIDE; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; RECEPTORS, ANTIGEN, B-CELL; RNA, MESSENGER; SRC-FAMILY KINASES; SUBCELLULAR FRACTIONS; SUBSTRATE SPECIFICITY; VIDARABINE;

EID: 84863104021     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039902     Document Type: Article

References (34)

1. Chong YP, Ia KK, Mulhern TD, Cheng HC, (2005) Endogenous and synthetic inhibitors of the Src-family protein tyrosine kinases. Biochim Biophys Acta 1754: 210-220.
2. Parsons SJ, Parsons JT, (2004) Src family kinases, key regulators of signal transduction. Oncogene 23: 7906-7909.
3. Frame MC, (2002) Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta 1602: 114-130.
4. Xu Y, Harder KW, Huntington ND, Hibbs ML, Tarlinton DM, (2005) Lyn tyrosine kinase: accentuating the positive and the negative. Immunity 22: 9-18.
5. Reth M, (1989) Antigen receptor tail clue. Nature 338: 383-384.
6. Dal Porto JM, Gauld SB, Merrell KT, Mills D, Pugh-Bernard AE, et al. (2004) B cell antigen receptor signaling 101. Mol Immunol 41: 599-613.
7. Harwood NE, Batista FD, (2008) New insights into the early molecular events underlying B cell activation. Immunity 28: 609-619.
8. Onabajo OO, Seeley MK, Kale A, Qualmann B, Kessels M, et al. (2008) Actin-binding protein 1 regulates B cell receptor-mediated antigen processing and presentation in response to B cell receptor activation. J Immunol 180: 6685-6695.
9. Lee F, Fandi A, Voi M, (2008) Overcoming kinase resistance in chronic myeloid leukemia. Int J Biochem Cell Biol 40: 334-343.
10. Pugh-Bernard AE, Cambier JC, (2006) B cell receptor signaling in human systemic lupus erythematosus. Curr Opin Rheumatol 18: 451-455.
11. Hussein K, von Neuhoff N, Busche G, Buhr T, Kreipe H, et al. (2009) Opposite expression pattern of Src kinase Lyn in acute and chronic haematological malignancies. Ann Hematol. 88: 1059-67.
12. Contri A, Brunati AM, Trentin L, Cabrelle A, Miorin M, et al. (2005) Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 115: 369-378.
13. Trentin L, Frasson M, Donella-Deana A, Frezzato F, Pagano MA, et al. (2008) Geldanamycin-induced Lyn dissociation from aberrant HSP90-stabilized cytosolic complex is an early event in apoptotic mechanisms in B-chronic lymphocytic leukemia. Blood 112: 4665-74.
14. Kitamura D, Kaneko H, Miyagoe Y, Ariyasu T, Watanabe T, (1989) Isolation and characterization of a novel human gene expressed specifically in the cells of hematopoietic lineage. Nucleic Acids Res 17: 9367-9379.
15. Brunati AM, Donella-Deana A, James P, Quadroni M, Contri A, et al. (1999) Molecular features underlying the sequential phosphorylation of HS1 protein and its association with c-Fgr protein-tyrosine kinase. J Biol Chem 274: 7557-7564.
16. Uruno T, Zhang P, Liu J, Hao JJ, Zhan X, (2003) Haematopoietic lineage cell-specific protein 1 (HS1) promotes actin-related protein (Arp) 2/3 complex-mediated actin polymerization. Biochem J 371: 485-493.
17. Suzuki Y, Demoliere C, Kitamura D, Takeshita H, Deuschle U, et al. (1997) HAX-1, a novel intracellular protein, localized on mitochondria, directly associates with HS1, a substrate of Src family tyrosine kinases. J Immunol 158: 2736-2744.
18. He H, Watanabe T, Zhan X, Huang C, Schuuring E, et al. (1998) Role of phosphatidylinositol 4,5-bisphosphate in Ras/Rac-induced disruption of the cortactin-actomyosin II complex and malignant transformation. Mol Cell Biol 18: 3829-3837.
19. Fukuda T, Kitamura D, Taniuchi I, Maekawa Y, Benhamou LE, et al. (1995) Restoration of surface IgM-mediated apoptosis in an anti-IgM-resistant variant of WEHI-231 lymphoma cells by HS1, a protein-tyrosine kinase substrate. Proc Natl Acad Sci U S A 92: 7302-7306.
20. Chen YR, Kori R, John B, Tan TH, (2001) Caspase-mediated cleavage of actin-binding and SH3-domain-containing proteins cortactin, HS1, and HIP-55 during apoptosis. Biochem Biophys Res Commun 288: 981-989.
21. Gomez TS, McCarney SD, Carrizosa E, Labno CM, Comiskey EO, et al. (2006) HS1 functions as an essential actin-regulatory adaptor protein at the immune synapse. Immunity 24: 741-752.
22. Scielzo C, Ghia P, Conti A, Bachi A, Guida G, et al. (2005) HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses. J Clin Invest 115: 1644-1650.
23. Ruzzene M, Penzo D, Pinna LA, (2002) Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. Biochem J 364: 41-47.
24. Ruzzene M, Brunati AM, Sarno S, Marin O, Donella-Deana A, et al. (2000) Ser/Thr phosphorylation of hematopoietic specific protein 1 (HS1): implication of protein kinase CK2. Eur J Biochem 267: 3065-3072.
25. Danilov AV, Danilova OV, Klein AK, Huber BT, (2006) Molecular pathogenesis of chronic lymphocytic leukemia. Curr Mol Med 6: 665-675.
26. Hamblin TJ, Oscier DG, (1997) Chronic lymphocytic leukaemia: the nature of the leukaemic cell. Blood Rev 11: 119-128.
27. Yamanashi Y, Fukuda T, Nishizumi H, Inazu T, Higashi K, et al. (1997) Role of tyrosine phosphorylation of HS1 in B cell antigen receptor-mediated apoptosis. J Exp Med 185: 1387-1392.
28. Scielzo C, Bertilaccio MT, Simonetti G, Dagklis A, ten Hacken E, et al. (2010) HS1 has a central role in the trafficking and homing of leukemic B cells. Blood 116: 3537-3546.
29. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK, (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94: 1848-1854.
30. Hamblin TJ, Orchard JA, Ibbotson RE, Davis Z, Thomas PW, et al. (2002) CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 99: 1023-1029.
31. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, et al. (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343: 1910-1916.
32. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, et al. (2003) ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348: 1764-1775.
33. Meulmeester E, Jochemsen AG, (2008) p53: a guide to apoptosis. Curr Cancer Drug Targets 8: 87-97.
34. Warr MR, Shore GC, (2008) Unique biology of Mcl-1: therapeutic opportunities in cancer. Curr Mol Med 8: 138-147.